If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Division of Growth and Development and Section of Orthodontics, UCLA School of Dentistry, Los Angeles, CaliforniaUCLA Division of Plastic and Reconstructive Surgery, Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center at UCLA, Los Angeles, California
Division of Growth and Development and Section of Orthodontics, UCLA School of Dentistry, Los Angeles, CaliforniaUCLA Division of Plastic and Reconstructive Surgery, Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center at UCLA, Los Angeles, CaliforniaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California
Division of Growth and Development and Section of Orthodontics, UCLA School of Dentistry, Los Angeles, CaliforniaUCLA Division of Plastic and Reconstructive Surgery, Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center at UCLA, Los Angeles, California
UCLA Division of Plastic and Reconstructive Surgery, Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center at UCLA, Los Angeles, California
Division of Growth and Development and Section of Orthodontics, UCLA School of Dentistry, Los Angeles, CaliforniaUCLA Division of Plastic and Reconstructive Surgery, Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center at UCLA, Los Angeles, California
UCLA Division of Plastic and Reconstructive Surgery, Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center at UCLA, Los Angeles, California
Address correspondence to Kang Ting, D.M.D., UCLA School of Dentistry, University of California, Los Angeles, Box 951668, CHS 30-113, Los Angeles, CA 90095-1668.
Chia Soo, M.D., (Correspondent for the Editorial and Production offices), UCLA Division of Plastic and Reconstructive Surgery and Department of Orthopaedic Surgery and the Orthopaedic Hospital Research Center, University of California, Los Angeles, Los Angeles, CA 90095-1579.
UCLA Division of Plastic and Reconstructive Surgery, Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center at UCLA, Los Angeles, California
The differentiation factor NEL-like molecule-1 (NELL-1) has been reported as osteoinductive in multiple in vivo preclinical models. Bone morphogenetic protein (BMP)-2 is used clinically for skeletal repair, but in vivo administration can induce abnormal, adipose-filled, poor-quality bone. We demonstrate that NELL-1 combined with BMP2 significantly optimizes osteogenesis in a rodent femoral segmental defect model by minimizing the formation of BMP2-induced adipose-filled cystlike bone. In vitro studies using the mouse bone marrow stromal cell line M2-10B4 and human primary bone marrow stromal cells have confirmed that NELL-1 enhances BMP2-induced osteogenesis and inhibits BMP2-induced adipogenesis. Importantly, the ability of NELL-1 to direct BMP2-treated cells toward osteogenesis and away from adipogenesis requires intact canonical Wnt signaling. Overall, these studies establish the feasibility of combining NELL-1 with BMP2 to improve clinical bone regeneration and provide mechanistic insight into canonical Wnt pathway activity during NELL-1 and BMP2 osteogenesis. The novel abilities of NELL-1 to stimulate Wnt signaling and to repress adipogenesis may highlight new treatment approaches for bone loss in osteoporosis.
NEL-like molecule-1 (NELL-1) is an osteoinductive growth factor first identified through its overexpression in pathologically fusing suture specimens from patients with craniosynostosis.
Conversely, Nell1 deficiency severely disrupts bone growth, as mice with nonsense mutations in Nell1 die perinatally with major skeletal anomalies in the craniofacial complex, spine, and long bones.
Siu RK, Zhang X, Ko T, Wu BM, Ting K, Culiat CT, Soo C: Nell-1 deficient mice exhibit abnormal structure in spinal and long bones. Presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research. 2009 September 11-14, Denver, CO
Highlighting the central role of NELL-1 in skeletal development, NELL-1 mediates key downstream effects of the master osteogenic regulator runt-related transcription factor 2 (RUNX2)
Recently, we demonstrated that osteoinductive effects of NELL-1 are partially mediated through binding to the intracellular molecule apoptosis related protein 3 and integrin-β1.
Based on these results demonstrating reproducible preclinical osteoinductivity in multiple small and large animal models, NELL-1 is being developed for therapeutic use in spinal fusion in humans.
Bone morphogenetic protein-2 (BMP2) is a U.S. Food and Drug Administration (FDA)–approved osteoinductive growth factor most commonly used for spinal fusions and treatment of skeletal defects.
Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
Based on data from nonhuman primates, the minimum effective human BMP2 concentration was initially set at 1.5 mg/mL (total dose, 4.2 to 12 mg) in pilot and pivotal trials in humans and is currently the approved concentration for clinical use.
Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
Unfortunately, the high BMP2 concentrations required for osteogenesis in humans are associated with significant adverse effects, including an FDA warning of life-threatening cervical swelling,
Thus, improving the safety and efficacy of BMP2-based skeletal repair is crucial. Although NELL-1 is being developed as a standalone osteoinductive therapeutic, we previously performed studies of NELL-1 and BMP2 in animals in an effort to better understand the molecular and cellular bases of NELL-1 and/or BMP2 osteoinductivity.
Because canonical Wnt is a major signal transduction pathway that regulates mesenchymal stem cell commitment to osteogenic over adipogenic lineages, we examined whether NELL-1 may synergize with BMP2 in bone formation through β-catenin–dependent Wnt signaling. Here we show NELL-1 activation of canonical Wnt signaling as a mechanistic basis for the observed NELL-1 inhibition of BMP2-induced adipogenesis and for NELL-1+BMP2 synergy in bone formation. Importantly, we establish NELL-1 as a novel Wnt pathway activator that can be applied, with BMP2 to improving the safety and efficacy of currently available bone-regeneration therapies. Overall, treatment with NELL-1+BMP2 forms bone of better quality than that formed with either NELL-1 or BMP2 alone.
Materials and Methods
Antibodies and Reagents
Human recombinant NELL-1 was purified by Aragen Bioscience (Morgan Hill, CA). Human BMP2 (Infuse Bone Graft) was purchased from Medtronic (Minneapolis, MN). Primary antibodies used in this study were anti–Runx2 (sc-10758; Santa Cruz Biotechnology, Santa Cruz, CA), anti–peroxisome proliferator-activated receptor γ (PPARγ; sc-7273; Santa Cruz Biotechnology), anti–CCAAT enhancer–binding protein α (C/EBPα) (ab63486-100; Abcam, Cambridge, MA), antiosteocalcin (sc-18322; Santa Cruz Biotechnology), anti–β-catenin (610153; BD Biosciences, Franklin Lakes, NJ), anti–active β-catenin (05-665; Millipore, Billerica, MA) and anti–β-actin (sc-1616; Santa Cruz Biotechnology). Recombinant mouse Wnt-3a protein (1324-WN-002) and Dickkopf-related protein 1 (Dkk1) (5897-DK-010) were purchased from R&D Systems (Minneapolis, MN). XAV939 was purchased from Cayman Chemical (Ann Arbor, MI).
Implant Material
Cylindrical poly(lactic-co-glycolic acid) (PLGA) scaffold implants were fabricated as described previously.
Briefly, 85/15 D,L-PLGA (inherent viscosity, 0.61 dL/g; Absorbable Polymers, Pelham, AL)/chloroform solutions were mixed with 200 to 300 μm–diameter sucrose to obtain 94% porosity and were compressed in a polytetrafluoroethylene mold to form scaffolds measuring 6 mm in length and 4 mm in diameter. After freeze-drying overnight, scaffolds were immersed in three changes of distilled deionized water (ddH2O) to dissolve the sucrose. All scaffolds were disinfected by immersion in 70% ethanol for 30 minutes, followed by three rinses with ddH2O.
Scaffolds were then coated with hydroxyapatite to ensure efficient NELL-1 and BMP2 loading and to enhance overall osteoconductivity of the hydrophobic PLGA scaffold. Briefly, two sterile, supersaturated solutions containing ion concentrations fivefold greater than those in human plasma [simulated body fluid (SBF) 1 and 2] were sequentially applied to the scaffolds. The ionic concentrations and preparation of SBF 1 and SBF 2 were previously published.
Immediately before the coating process, dried PLGA scaffolds were subjected to glow discharge argon plasma etching (Harrick Scientific, Ossining, NY) to improve wetting and coating uniformity. Etched PLGA scaffolds were then incubated in SBF 1 for 12 hours and changed to SBF 2 for another 12 hours at 37°C inside of a water-jacketed incubator. Coated PLGA scaffolds were rinsed gently with sterile ddH2O to wash away excess sodium chloride solution and were dried in the laminar flow hood. The thickness of the hydroxyapatite coating was 40 to 100 nm. Apatite-coated PLGA scaffolds did not exhibit a reduction in porosity and maintained the same pore interconnectivity and pore size ranging between 200 and 300 μm.
Before implantation, scaffolds were impregnated with recombinant human BMP2 and/or recombinant human NELL-1. Doses of each growth factor (Table 1) were chosen based on the ability of BMP2 to consistently induce adipocytic bone cysts
Each growth factor was diluted to the appropriate concentration in phosphate-buffered saline (PBS), added dropwise uniformly to the scaffolds for 20 minutes, and lyophilized in a freeze-drier overnight at −20°C. Implants for PBS controls were generated in the same way, except that no growth factors were added.
Table 1Experimental Groups for FSD Surgeries
Experimental group, concentration
Number of animals
Scaffold volume, μL
Total dose, μg
NELL-1
BMP-2
8 weeks
PBS only (control)
3
75
0
0
300 μg/mL BMP2
3
75
0
22.5
600 μg/mL BMP2
3
75
0
45
600 μg/mL NELL-1 + 300 μg/mL BMP2
3
75
45
22.5
600 μg/mL NELL-1 + 600 μg/mL BMP2
3
75
45
45
2 weeks
PBS only (control)
3
75
0
0
600 μg/mL BMP2
3
75
0
45
600 μg/mL NELL-1
3
75
45
0
600 μg/mL NELL-1 + 600 μg/mL BMP2
3
75
45
45
BMP2, bone morphogenetic protein 2; FSD, femoral segmental defects; NELL-1, NEL-like molecule-1; PBS, phosphate-buffered saline.
All animal procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the University of California (Los Angeles, CA) were and approved by the Chancellor's Animal Research Committee. Twenty-seven male Lewis rats, aged 3 months, were purchased from Taconic Farms (Hudson, NY) and assigned to experimental groups as shown in Table 1. The FSD model was performed as previously described.
Briefly, a 25- to 30-mm longitudinal incision was aseptically made over the anterolateral aspect of the femur, and the overlying muscles were separated to expose the femoral shaft. For fixation, a polyethylene plate (length, 23 mm; width, 4 mm; height, 4 mm) was placed on the anterolateral surface of the femur and secured with four 0.9 mm–diameter threaded Kirschner wires drilled through the plate and both cortices of the femur. Two 26-gauge stainless steel cerclage wires were tightened around the plate and bone for additional stability. With a small, oscillating saw blade (Stryker, Kalamazoo, MI), a 6-mm, critical-sized, mid-diaphyseal defect was generated. The volume of the defect was approximately 75 mL. An implant was placed into the defect, and then the overlying muscle, fascia, and skin were closed with 4–0 Vicryl absorbable suture (Ethicon, Somerville, NJ). Animals were sacrificed at 2 and 8 weeks after surgery.
3D Microcomputer Tomography Evaluation
After sacrifice, rat femurs were scanned by high-resolution three-dimensional (3D) microcomputer tomography (microCT) (SkyScan 1172F; Bruker microCT N.V., Kontich, Belgium) at an image resolution of 27.4 μm (55 kV and 181 μÅ radiation source, using a 0.5-mm aluminum filter) and analyzed using DataViewer, Recon, CTAn, and CTVol software version 1.15.7.0+ provided by the manufacturer (Bruker microCT N.V.). All quantitative and structural morphometric data use nomenclature described by the Nomenclature Committee of the American Society for Bone and Mineral Research.
The global thresholding principle was applied for a threshold of 100 to all samples to isolate mineralized bone for bone volume and tissue volume measurements and calculations. Two-dimensional (2D) X-ray images were obtained by the creation of an axial cut through the center of the defect area. A volume of interest of 500 slices (approximately 10 mm) centered on the middle of the defect was selected for sagittal sections and 3D reconstruction. Sagittal sectional images were generated through the mediolateral center of the femur. A volume of interest of 50 slices (approximately 1 mm) centered on the middle of the defect was reconstructed for axial sectional images. Bone volume and tissue volume measurements were calculated from analyses performed for a volume of 300 slices (approximately 6 mm).
Biochemical Analysis
Finite element (biomechanical) analysis was performed using microCT images converted to DICOM files using SkyScan DICOM converter software (DicomCT application, SkyScan 1172F) according to our prior methods.
Tetrahedral 3D mesh models were generated using a random volume of interest within the defect site (size, 0.5 mm3) using ScanIP software version 7 (Simpleware Ltd., Exeter, UK). Finite element analyses were performed using the ABAQUS software version 6.12 (Dassault Systèmes, Forest Hill, MD) with boundary conditions set as encastre, constrained in all directions. Next, we applied a uniform compressive pressure of 0.5 MPa on the superior surface of the volume of interest. The von Mises stress in the samples was recorded.
Histological, Immunohistochemical, and Histomorphometric Analysis
Hematoxylin and eosin (H&E), Masson's trichrome, and immunohistochemical staining were performed as previously described.
Briefly, tissues were embedded in paraffin, sectioned into 5-μm slices, and deparaffinized and rehydrated before antibody addition. All primary antibodies were used at a dilution of 1:100. Appropriate secondary antibodies (Dako North America, Inc, Carpinteria, CA) were used at a dilution of 1:200. Photomicrographs were acquired using Olympus BX51 (×40, ×200, and ×400 magnification lens, UPLanFL; Olympus, Center Valley, PA) and SZX12 microscopes (×10 magnification lens, DF PLAPO 1.2× pf; Olympus) and a MicroFire digital microscope camera with ImageFrame software version 2.1 (Optronics, Goleta, CA). Staining intensity was quantified using ImagePro Plus (Media Cybernetics, Rockville, MD). Results are reported as the intensity measurements from eight random fields at ×200 magnification.
Oil red O staining was performed on 10-μm frozen sections using a 0.3% oil red O solution in 60% isopropyl alcohol/40% ddH2O for 15 minutes. Slides were counterstained with hematoxylin for 15 seconds to visualize nuclei. The intensity of oil red O–positive staining was quantified using ImagePro Plus in eight separate random fields at ×200 magnification.
Histomorphometric analyses were performed on H&E–stained sections. Only regions within the defect region containing newly formed trabecular bone were analyzed. The histomorphometric parameters of bone area, tissue area, trabecular number, trabecular perimeter, trabecular width, and trabecular spacing were measured at ×100 magnification and analyzed using Photoshop CS5 (Adobe Systems, San Jose, CA) as previously described.
Five sections per specimen were analyzed. All histomorphometric measurements in each specimen were assessed blindly (X.Z., J.S., and K.S.L.), and all nomenclature, symbols, and units are used per established American Society for Bone and Mineral Research conventions.
was purchased from ATCC (Manassas, VA). Cells were maintained in growth medium [RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum, 1 mmol/L sodium pyruvate, and 100 U/mL penicillin/streptomycin]. Osteogenic differentiation medium consisted of RPMI 1640, 10% FBS, 50 μg/mL ascorbic acid, and 3 mmol/L β-glycerophosphate. Growth medium only was used for adipogenic differentiation studies as previously reported.
Primary human BMSCs were purchased from PromoCell (Heidelberg, Germany). Cells were cultured using Mesenchymal Stem Cell Growth Medium (C-28010; PromoCell). In vitro osteogenesis and adipogenesis were induced by mesenchymal stem cell osteogenic differentiation medium (Mesenchymal Stem Cell Growth Medium plus 50 μg/mL ascorbic acid and 3 mmol/L β-glycerophosphate)
and Mesenchymal Stem Cell Adipogenic Differentiation Medium (C-28011; PromoCell).
For osteogenic or adipogenic differentiation, M2-10B4 cells or human BMSCs were seeded at 1 × 105 cells per well or 8 × 104 cells per well, respectively, in 24-well plates for 24 hours, and then cultured with differentiation medium with NELL-1 and/or BMP2.
RNA Extraction, Real-Time PCR, and Immunoblot Analysis
Total RNA extraction and real-time PCR were performed as previously described.
SYBR green real-time PCR primer sequences for mouse M2-10B4 cells are given in Table 2. For human BMSCs, TaqMan primer-probe sets HS99999905_m1 (glyceraldehyde-3-phosphate dehydrogenase), Hs01115513-m1 (PPARγ), Hs02915002-s1 (C/EBPα), Hs00609452-g1 [osteocalcin (OCN)], and Hs00959010-m1 [osteopontin (OPN)] were used (Applied Biosystems, Carlsbad, CA). All fold-change values from three independent experiments are reported.
Nuclear and cytoplasmic proteins were isolated using an NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific, Rockford, IL). Western blot analysis was performed as previously described
using antibodies against PPARγ, C/EBPα, and β-catenin at a dilution of 1:1000.
In Vitro Staining and Alkaline Phosphatase Activity Assay
For oil red O staining of cultured cells, monolayers were rinsed with PBS, fixed with 10% formalin for 1 hour at room temperature, and stained with 3% oil red O solution (see Histological, Immunohistochemical, and Histomorphometric Analysis) for 10 minutes. Adipocytes were quantified through counting of oil red O–positive cells in four wells per experimental condition. Results are reported from 16 random fields at ×200 magnification. Alizarin red staining and alkaline phosphatase activity assays were performed as previously described.
M2-10B4 cells were seeded on Millicell EX Slides (PEZGS0816, Millipore) at 5 × 104 cells per well in RPMI 1640 + 10% FBS for 24 hours and serum starved in RPMI 1640 + 1% FBS overnight. After 2 hours of treatment, cells were fixed using ice-cold acetone for 10 minutes. Anti–active β-catenin antibody (Millipore) was applied at a dilution of 1:200. ABC complex (Vector Laboratories, Burlingame, CA) was applied to the sections after incubation with biotinylated secondary antibody (Dako). AEC Substrate (Dako) was used as a chromogen, and the sections were lightly counterstained with hematoxylin. Photomicrographs were acquired using an Olympus BX51 device (×200 UPLanFL magnification lens).
Luciferase Reporter Assay
M2-10B4 cells were transfected with 20 μg of Super(16×)TOPFLASH (TCF/LEF reporter plasmid) and 1 μg of Renilla luciferase plasmids for 24 hours and then seeded at 4.0 × 103 cells per well in 96-well plates. Cells were starved in RPMI 1640 + 1% FBS overnight and then treated with BMP2 and/or NELL-1. Luciferase activity was measured 48 hours after treatment using Dual Luciferase Reporter Assay System (Promega, Madison, WI) per the manufacturer's instructions.
Preparation of Lentiviral Vectors for Runx2 Reporter Assays
The transduction plasmid for preparing lentiviral vector carrying the Runx2 P1-enhanced green fluorescent protein (EGFP) expression cassette (Runx2-EGFP reporter) was prepared by substituting the cytomegalovirus promoter in the pRRL-cPPT-CMV-X-PRE-SIN plasmid
Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression.
with the mouse Runx2 P1 promoter. The mouse Runx2 P1 promoter was obtained by PCR of mouse genomic DNA (forward primer, 5′-GCGAATTACTCGAGAGCAGCACTGTTGCTCAGAA-3′; reverse primer, 5′-GCGAATGCCCGGGTCACACAATCCAAAAAAGC-3′). 293T cells were cotransfected with the transduction plasmids, the package plasmid pCMV-dR8.2-vprX, and the envelope plasmid pCMV-VSVG.
The viral vectors were collected at 2 to 4 days after transfection and were filtered, and concentrated. The concentrations of viral vector were quantified by a count of the core protein p24 by enzyme-linked immunosorbent assay as previously described.
M2-10B4 cells were seeded in 24-well cell culture plates at 2 × 104 cells per well 16 hours before infection. Viral vectors with p24 counts of 0.4 μg were added to each well in 24-well plates. Three hours after infection, the viral vectors were washed away, and fresh medium was added to the cultures. At 24 hours after infection, BMP2 and/or NELL-1 were added into the culture media.
Flow Cytometric Assay of GFP-Positive Cells
Cells were trypsinized and collected 3 days after infection. Flow cytometry was performed to quantify GFP expression in the collected cells using a Cytomics FC500 cell sorter (Beckman Coulter, Brea, CA). Cells infected with mock vector were used as the negative control to establish gates. The percentages of GFP-positive cells were counted to quantify the expression of GFP in the infected cultures.
Statistical Analysis
Means ± SDs were calculated from numerical data. To allow for multiple comparisons between groups, statistical analyses were performed using one-way analysis of variance for single-variable comparisons and two-way analysis of variance for dual-variable comparisons (ie, experiments involving both Dkk or XAV939 and BMP2 and/or NELL-1). This procedure was followed by a post hoc Tukey range test to directly compare the data between the two groups. P < 0.05 was considered to be significant for all statistical tests used.
Results
NELL-1 Inhibits BMP2-Induced Cystlike Bone Formation in Vivo
Although the 300 and 600 μg/mL BMP2 concentrations used here are less than the 1.5 mg/mL concentration used clinically, these concentrations are sufficient for reproducible induction of abnormal bone formation in a rat FSD model, as we have previously described.
In addition, we used NELL-1 at 600 μg/mL because we previously showed that this NELL-1 concentration in a demineralized bone matrix carrier was able to induce fusion in an FSD model.
PLGA scaffolds containing PBS, BMP2, or NELL-1+BMP2 combined, were implanted into rat FSDs (Figure 1A).
Figure 1Microcomputer tomography (microCT) and biomechanical evaluation of femoral segmental defects (FSDs) at 8 weeks after surgery reveals induction of cystlike bone formation with bone morphogenetic protein 2 (BMP2) alone and suppression of this effect by addition of NEL-like molecule-1 (NELL-1). BMP2 dose: 300 or 600 μg/mL. NELL-1 dose: 600 μg/mL. A: Left panel, schematic of FSD surgical procedure; middle panel, hydroxyapatite-coated PLGA scaffold implanted into defect; right panel, intraoperative photograph after scaffold implantation. B–D: From top to bottom, two-dimensional (2D) radiography, sagittal section, axial section, and three-dimensional (3D)-reconstructed microCT images (B). Green boxes indicate the region of interest selected for microCT reconstruction below. BMP2 treatment results in formation of abnormal bone extending beyond the cortical margins, which is not observed with NELL-1+BMP2 co-treatment. Red boxes indicate the region of interest selected for quantification of bone volume (C) and tissue volume (D). E: Finite element analysis and quantification of von Mises stress. Data are expressed as means ± SD. ∗P < 0.05, ∗∗P < 0.01 versus control group; †P < 0.05 versus same dose of BMP2. n = 3 (C and D). Scale bar = 5 mm (B).
We performed high-resolution 2D radiography and 3D microCT reconstructions of the defect sites 8 weeks after surgery. Control defects treated with PBS exhibited definitive non-union. In contrast, BMP2 treatment alone resulted in bone fusion, but the newly formed bone was characterized peripherally by a thin, continuous cortical shell that extended well beyond the original bony defect margins and internally by sparse and thin trabeculae formation. Strikingly, NELL-1+BMP2 cotreatment produced bone fusion, with newly formed bone confined mostly to the defect sites with considerably thicker cortical architecture and a much denser, native bonelike, trabecular structure compared with the BMP2-only group (Figure 1B). Notably, NELL-1 on PLGA scaffolds increased bone regeneration compared with that in controls, but did not induce bony fusion at up to 12 weeks after surgery (Supplemental Figure S1), unlike NELL-1 on demineralized bone matrix scaffolds.
On quantitative microCT analysis of bone volume and tissue volume (Figure 1, C and D, respectively), all treatments significantly increased bone volume compared with no treatment; however, no statistically significant difference in bone volume between the BMP2-only and NELL-1+BMP2 cotreatment groups was observed. On the other hand, NELL-1+BMP2 cotreatment significantly reduced tissue volume compared with BMP2 treatment alone. Moreover, computer-simulated biomechanical (finite element analysis) testing demonstrated increased bone strength with BMP2+NELL-1 cotreatment compared with BMP2 only (Figure 1E). Taken together, these measurements indicate that similar amounts of bone were induced by either BMP2 treatment alone or NELL-1+BMP2 cotreatment, but the bone was distributed throughout a larger volume of tissue with BMP2-only treatment compared with NELL-1+BMP2 cotreatment.
We next analyzed the bone quality of FSDs treated with PBS only (control), BMP2 alone, or NELL-1+BMP2 by histological examination of specimens collected at 8 weeks after surgery (Figure 2). The control defects exhibited definitive fibrous non-union of the femoral cortices, with no trabecular bone formation at the defect centers. BMP2 treatment alone induced fracture union, but the newly formed bone contained exuberant adipose tissue interspersed with sparse trabecular bone that was surrounded by a thin cortical bone shell extending up to approximately 4 mm beyond the original bone defect margins. In contrast, NELL-1+BMP2 cotreatment generated tightly woven, trabecular bone largely confined to the defect sites. Histomorphometric analyses on serial H&E-stained sections showed increased bone area/tissue area ratio, trabecular number, perimeter, and width, and reduced trabecular spacing in NELL-1+BMP2 treated samples. Masson's trichrome staining and immunostaining for osteocalcin (Ocn), a marker of bone matrix and osteoblastic differentiation, confirmed that NELL-1+BMP2 cotreated defects exhibited increased bone formation with denser trabeculations than with BMP2 treatment alone. To specifically assess and quantify adipogenic differentiation observed by H&E and Masson's trichrome histological examination, we performed oil red O staining on cryosectioned specimens. Consistent with our previous histological findings,
BMP2 treatment alone significantly increased the intensity of oil red O staining, an effect notably absent with NELL-1+BMP2 cotreatment.
Figure 2Histological evaluation at 8 weeks after surgery reveals increased osteogenesis with NEL-like molecule-1 (NELL-1) + bone morphogenetic protein 2 (BMP2) cotreatment and reduction of adipogenesis induced by BMP2. BMP2 dose, 600 μg/mL; NELL-1 dose, 600 μg/mL. A: Hematoxylin and eosin (H&E) staining reveals a large extension of bone surrounded by thin cortical bone in BMP2-only samples, which is not observed in phosphate-buffered saline control or NELL-1+BMP2 co-treated samples. The boxed areas indicate the regions magnified in B. Boundaries of defect are as indicated. Histomorphometric analyses are based on H&E staining. B: Masson's trichrome staining reveals fibrous tissue (light blue) in control samples, abundant adipocytes (large white droplets) in BMP2-only samples, and osteoid matrix (dark blue) ossifying into mature trabecular bone (red) in NELL-1+BMP2 co-treated samples. C: Osteocalcin (Ocn) immunohistochemical analysis. Arrowheads indicate positive Ocn staining and its quantification. D: Oil red O staining and its quantification. Data are expressed as means ± SD. ∗P < 0.05, ∗∗P < 0.01 versus control group; ††P < 0.01 versus same dose of BMP2. n = 3 (B and D). Scale bars: 4 mm (A), 1 mm (B), 0.2 mm (C), 0.4 mm (D). Def, extent of defect area; Tb. N, trabecular number; Tb. Pm., trabecular perimeter; Tb.Sp, trabecular spacing; Tb.Wi, trabecular width.
To gain better insight on the early cellular effects of NELL-1 and BMP2 on defect healing, we evaluated NELL-1, BMP2, or NELL-1+BMP2 treated FSDs at 2 weeks after surgery (Figure 3). Our published findings show that Nell-1 does not form ectopic bone,
Instead, new bony trabeculations arising from the cut femoral bone ends were observed growing into the defect. In contrast, BMP2-only samples exhibited a massive reactive tissue zone characterized by increased cellularity in the muscle and bone defect compartments that extended well beyond the original margins of the bone defect site. Meanwhile, NELL-1+BMP2 cotreatment induced a much smaller reactive tissue zone, with increased trabecular bone largely confined to the original bone defect area, and with minimal tissue reactivity in the muscle compartment. Together, our microCT and histological data indicate that NELL-1 reduces BMP2-induced exuberant bone formation and adipogenesis to improve BMP2-mediated osteogenesis.
Figure 3Histological evaluation at 2 weeks after surgery. A: Hematoxylin and eosin (H&E) staining demonstrates increased cellularity and aberrant expansion of bone tissue into the muscle compartment with bone morphogenetic protein 2 (BMP2) treatment alone as early as 2 weeks, but not with NEL-like molecule-1 (NELL-1) treatment alone or NELL-1+BMP2 cotreatment. The boxed areas indicate the regions magnified in B. Arrowheads indicate the lateral limit of new tissue formation. BMP2 dose: 600 μg/mL; NELL-1 dose, 600 μg/mL. B: Trichrome staining for mature mineralized bone (red) and osteoid matrix (blue). Please note that the implanted scaffold also appears red. In the defect site, NELL-1+BMP2 cotreatment induces more trabecular bone than does BMP2 treatment alone, but BMP2 alone also increases cellularity and induces a tissue reaction containing poorly trabeculated bone and fibrous tissue outside of the cortical margin of the defect. The same location in the other groups contains primarily muscle tissue only. n = 3 (B). Scale bars: 4 mm (A), 1 mm (B). Def, extent of defect area.
We previously observed that goat BMSCs transduced with adenoviral BMP2 and injected into nude mouse muscle pouch models form large bone voids filled with fatty tissue.
Furthermore, forced Nell1 and Bmp2 overexpression by adenoviral treatment produces more bone than either adenoviral Nell1 or Bmp2 alone in a nude mouse muscle pouch model.
To further analyze the effects of NELL-1 on BMP2-induced adipogenesis, we focused on the expression of Pparγ and C/Ebpα, two important transcriptional regulators of adipogenesis
(Figure 4). PPARγ immunohistochemistry of the increased adipogenesis observed by histological examination was used for analyzing FSD specimens collected 2 weeks after surgery. Samples treated with BMP2 alone exhibited strong Pparγ staining in the cells surrounding and between the trabeculae at the defect center, consistent with increased adipogenesis. Importantly, NELL-1 significantly repressed BMP2-induced Pparγ expression in NELL-1+BMP2 cotreated animals. We next sought to replicate these findings in vitro using the mouse BMSC line M2-10B4 under adipogenic conditions, as previously described.
At 9 days, BMP2-induced lipid accumulation was increased more than fivefold, as assessed by oil red O staining. However, the addition of NELL-1 antagonized the proadipogenic effects of BMP2 and significantly reduced both Pparγ and C/Ebpα expression. Because the effects of BMP2 on BMSCs may be species dependent,
and because cell lines may respond differently from primary cells, we also confirmed the inhibitory effects of NELL-1 on BMP2-induced adipogenesis using primary rat BMSCs (Supplemental Figure S2A) and primary human BMSCs. These data confirm that NELL-1 inhibits BMP2-stimulated adipogenesis in vitro in BMSCs from multiple species.
Figure 4Addition of NEL-like molecule-1 (NELL-1) reduces bone morphogenetic protein 2 (BMP2)-induced adipogenesis. A: Peroxisome proliferator-activated receptor γ (PPARγ) immunohistochemical analysis of femoral segmental defects (FSDs; within the scaffold implant) at 2 weeks after surgery reveals increased expression induced by BMP2 treatment alone but not NELL-1+BMP2 cotreatment. BMP2 dose, 600 μg/mL; NELL-1 dose, 600 μg/mL. Quantitation of PPARγ staining is show in graph to the right. B–D: M2-10B4 cells were treated with phosphate-buffered saline (PBS) only (control), 800 ng/mL NELL-1, and/or 300 ng/mL BMP2 under adipogenic differentiation. The expression of PPARγ and CCAAT enhancer–binding protein α (C/EBPα) was determined on day 3 by real-time PCR (B) and Western blot analysis with quantification of PPARγ and C/EBPα (C). D: Lipid accumulation was visualized by oil red O staining at 9 days and quantified by light microscopy from eight random areas. E: Real-time PCR analysis of PPARG and CEBPA expression in human primary bone marrow stromal cells (BMSCs) treated with PBS, 800 ng/mL NELL-1, and/or 300 ng/mL BMP2 for 2 days. All fold-changes are reported relative to control group. Data are expressed as means ± SD. ∗P < 0.05, ∗∗P < 0.01 versus control group; †P < 0.05, ††P < 0.01 versus same dose of BMP2. n = 3 (A, C, and E), n = 4 (D). Scale bars = 0.2 mm (A and D).
To determine whether the suppression of adipogenesis corresponded with an increase in osteogenesis, we analyzed Runx2 expression in the centers of FSDs collected 2 weeks after surgery (Figure 5A). Runx2 expression was significantly increased with NELL-1+BMP2 cotreatment compared with BMP2 treatment alone. To model this effect in vitro, M2-10B4 cells were cultured under osteogenic conditions (Figure 5, B and C). As expected, NELL-1 and BMP2 alone increased the expression of markers of early (Runx2 expression), intermediate (alkaline phosphatase and osteopontin), and terminal osteogenic differentiation (osteocalcin expression and alizarin red–positive bone nodules) over those in controls. However, when added together, NELL-1+BMP2 significantly increased all osteogenic markers relative to NELL-1 or BMP2 alone, consistent with our 8-week imaging and histological findings of high-quality bone formation. Repeating these experiments in primary human BMSCs (Figure 5D) showed that NELL-1 significantly increased OCN and OPN expression in human BMSCs in combination with BMP2.
Figure 5Addition of NEL-like molecule-1 (NELL-1) enhances bone morphogenetic protein 2 (BMP2)-induced osteogenesis. A: Expression of runt-related transcription factor 2 (Runx2) in NELL-1 and BMP2-treated samples of femoral segmental defect (FSD; within the scaffold implant) at 2 weeks after surgery. BMP2 dose, 600 μg/mL; NELL-1 dose, 600 μg/mL. Runx2-positive cells appear primarily adjacent to trabecular bone. Quantification of Runx2 staining is shown in graph to the right. B and C: M2-10B4 cells were treated with phosphate-buffered saline, 800 ng/mL NELL-1, and/or 100 ng/mL BMP2 under osteogenic differentiation conditions. B: Real-time PCR analysis of osteogenic differentiation marker gene. Runx2 expression was assessed at 1, 3, and 6 days; ALP expression was assessed at 3, 6, and 9 days; Ocn and Opn expressions were analyzed at 6, 9, and 12 days. C: Mineralization was visualized by Alizarin red staining at 12 days and quantified by light microscopy from eight random areas. D: Real-time PCR analysis of OCN and OPN expressions in human primary bone marrow stromal cells (BMSCs) treated with NELL-1 and/or BMP2 for 6 days. All fold-changes are reported relative to control group. Data are expressed as means ± SD. ∗P < 0.05, ∗∗P < 0.01 versus control group; †P < 0.05, ††P < 0.01 versus same dose of BMP2. n = 3 (A, B, and D), n = 4 (C). Scale bars = 0.2 mm (A and C).
we hypothesized that NELL-1–mediated effects may involve canonical Wnt activation. We first examined in vitro activation of canonical Wnt signaling by immunocytochemical staining of M2-10B4 cells using an antibody against active β-catenin (Figure 6A). BMP2 did not induce β-catenin nuclear accumulation at either 100 ng/mL or 300 ng/mL, whereas NELL-1+BMP2 cotreatment stimulated more β-catenin nuclear accumulation compared with BMP2 alone. Next, Western blot analysis of M2-10B4 cytoplasmic and nuclear fractions (Figure 6B) showed significantly increased nuclear β-catenin levels after treatment with NELL-1+BMP2 compared with BMP2 only. Similarly, the TOPFlash canonical Wnt reporter assay demonstrated no luciferase activity induced by BMP2, and restored luciferase activity induced by NELL-1+BMP2 (Figure 6C). Next, we examined in vivo activation of Wnt signaling by immunohistochemical staining for β-catenin (Figure 6D) in the same FSD specimens used for Pparγ (Figure 4A) and Runx2 (Figure 5A) staining. Increased nuclear β-catenin localization was observed only in NELL-1+BMP2 cotreatment groups. The BMP2-alone group revealed primarily cytoplasmic β-catenin staining. Taken together, these in vitro and in vivo results demonstrate a novel NELL-1 function to induce canonical Wnt activity and suggest that NELL-1 regulation of BMP2-induced osteogenesis and adipogenesis may occur through activation of canonical Wnt signaling.
Figure 6NEL-like molecule-1 (NELL-1) induces canonical Wnt pathway activity in vivo and in vitro. A: M2-10B4 cells were treated with indicated doses of bone morphogenetic protein 2 (BMP2) or BMP2+NELL-1 in RPMI 1640+1% fetal bovine serum for 2 hours and stained for active β-catenin. Recombinant Wnt-3a (100 ng/mL) was used as a positive control. B: Western blot analysis of nuclear and cytoplasmic fractions of β-catenin 2 hours after treatment under the same conditions as A. Quantitation of nuclear and cytoplasmic β-catenin shown in graphs to the middle and right. C: M2-10B4 cells were transfected with Super (16×) TOPFlash and Renilla luciferase plasmids. Cells were treated with indicated doses of BMP2 or BMP2+NELL-1 for 48 hours. The luciferase activity was normalized to control. D: Immunohistochemical analysis for β-catenin expression in BMP2 or BMP2+NELL-1 treated samples of femoral segmental defect (within the scaffold implant) at 2 weeks after surgery. BMP2 dose, 600 μg/mL; NELL-1 dose, 600 μg/mL. Arrowheads highlight positive nuclear staining for β-catenin. Quantitation of β-catenin staining is show in graph to the right. Insets and boxed areas indicate areas of magnification. E: Intact canonical Wnt signaling is required for anti-adipogenic and pro-osteogenic effects of NELL-1. M2-10B4 cells were seeded at the density of 1 × 105 cells per well in 24-well plates for 24 hours and treated with phosphate-buffered saline, 300 ng/mL BMP2, or 300 ng/mL BMP2 + 800 ng/mL NELL-1 under adipogenic differentiation conditions with or without 100 ng/mL Dickkopf-related protein 1 (DKK1) or with or without 1 μmol/L XAV-939 for 3 days. Peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer–binding protein α (C/EBPα) expression was measured by real-time PCR. F, top graph: M2-10B4 cells were seeded at the density of 1 × 105 cells per well in 24-well plates for 24 hours and treated with PBS, 300 ng/mL BMP2, or 300 ng/mL BMP2 + 800 ng/mL NELL-1 under osteogenic differentiation conditions with or without DKK1 for 3 days. Runx2 expression was measured by real-time PCR. Bottom graph: M2-10B4 cells were transduced with Runx2-enhanced green fluorescent protein reporter lentivirus and treated with PBS, 300 ng/mL BMP2, or 300 ng/mL BMP2 + 800 ng/mL NELL-1 with or without 1 μmol/L XAV939 24 hours after transduction. Runx2 reporter assay was performed on transduced cells after 3 days. All fold changes are reported relative to control group. Data are expressed as means ± SD. ∗P < 0.05, ∗∗P < 0.01 versus control group; †P < 0.05, ††P < 0.01 versus same dose of BMP2; ‡P < 0.05, ‡‡P < 0.01 versus no inhibitor treatment. n = 3 (A, B, D, and F), n = 4 (C). Scale bars = 0.1 mm (A; D, insets); 0.04 mm (D, boxed area).
Canonical Wnt Signaling Is Required for NELL-1 Effects on BMP2-Induced Lineage Differentiation
To determine whether NELL-1 repression of BMP2-induced PPARG and CEBPA expression requires Wnt activity, we treated M2-10B4 cells with two specific inhibitors of canonical Wnt signaling: recombinant mouse Dkk1and the small molecule XAV939 (Figure 6E). Dkk1 functions as an antagonist of canonical Wnt signaling by binding to low-density lipoprotein receptor–related protein (Lrp)5/6 and preventing its interaction with Wnt-Frizzled complexes.
By itself, each Wnt inhibitor increased expression of Pparg and Cebpa when added BMP2 alone. Importantly, NELL-1 suppression of BMP2-induced Pparg or Cebpa expression was largely reversed by Wnt signaling inhibition.
To determine whether Wnt signaling is required for NELL-1 augmentation of BMP2-mediated osteogenesis, we added DKK1 to NELL-1+BMP2-treated M2-10B4 cells. DKK1 eliminated the synergistic increase in Runx2 expression induced by NELL-1 addition to BMP2 (Figure 6F). M2-10B4 cells were also transduced with a lentiviral vector containing the Runx2 P1 promoter driving Gfp expression. Treatment of the transduced cells with BMP2 or BMP2+NELL-1 increased Runx2 P1–driven Gfp expression. Moreover, when XAV939 was added, significant inhibition of Runx2 P1 expression was found in NELL-1+BMP2 co-treated cells (Figure 6F). Collectively, these data indicate that NELL-1 regulation of Runx2, PPARγ, and C/EBPα, key transcription factors induced by BMP2 that dictate osteogenic and adipogenic lineage specification, is dependent on intact canonical Wnt signaling.
Discussion
In this study, we identified NELL-1 as a novel Wnt regulator that can suppress adipogenesis and promote osteogenesis in the context of the high BMP2 doses used clinically. We also demonstrated the ready feasibility of combining NELL-1 with BMP2 to significantly improve the clinical safety and efficacy of BMP2-based bone regeneration.
Proposed Molecular Mechanisms of NELL-1 and BMP2 Effects on Osteogenesis
The ability of NELL-1 to improve BMP2-induced bone quality can be explained in terms of their mechanistic effects on the master osteogenic and adipogenic regulators Runx2 and PPARγ, respectively. BMP2 induces osteogenic differentiation of mesenchymal progenitor cells by activating Runx2 expression through the action of the Smad family of transcription factors.
Importantly, increased PPARγ expression antagonizes Runx2, which in turn inhibits the osteogenic differentiation of mesenchymal progenitor cells, resulting in inconsistent bone formation.
Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways.
Co-immunoprecipitation and surface plasmon resonance experiments indicate that NELL-1 does not physically interact with BMP2 (data not shown), and we and others have established that NELL-1 does not participate in the Smad1/5/8 pathways (Supplemental Figure S2B),
suggesting that NELL-1 activates Runx2 via a mechanism independent of the BMP/Smad pathways.
In the present study, we describe NELL-1 stimulation of Runx2 expression and activity via canonical Wnt signaling, which is essential for differentiation of progenitor cells into osteoblasts and normal fetal bone development.
Because we showed that NELL-1 significantly increased the nuclear accumulation of β-catenin, it is possible that Runx2 expression may be likewise stimulated to induce osteoblastogenesis. Thus, NELL-1 is not only regulated by Runx2 and acts as its downstream mediator, but NELL-1 may also regulate Runx2 via canonical Wnt signaling. In addition to transcriptional regulation by BMP2, Runx2 physically interacts with Smad proteins to form active transcriptional complexes for osteogenic gene expression, resulting in the synergy between Runx2 and BMP2.
NELL-1 reduction of PPARγ expression was blocked by canonical Wnt inhibitors, indicating that NELL-1 down-regulation of adipogenesis was dependent on intact Wnt signaling. It was recently reported that BMP2 represses Wnt signaling during bone repair in a 1-mm in vivo monocortical trephine defect model.
In contrast, our data show lack of BMP2 induction, rather than repression per se, of canonical Wnt signaling. This discrepancy may be due to differences in defect size (ie, 6-mm full-thickness FSD versus 1-mm monocortical trephine defect) and origin of bone-forming progenitor cells (ie, bone marrow, periosteum, or surrounding soft tissues). Irrespectively, the up-regulation of Wnt by NELL-1 can explain the ability of NELL-1+BMP2 cotreatment to increase osteogenesis while simultaneously decreasing adipogenesis. Collectively, NELL-1 promotes BMP2 osteogenesis by both up-regulating Runx2 and down-regulating PPARγ via canonical Wnt signaling.
Previously we identified NELL-1–integrin-β1 binding as essential for the NELL-1–mediated activation of Wnt signaling.
In this study, we showed that Dkk1 blocked NELL-1 regulation of BMP2–induced osteogenesis and adipogenesis. Because DKK1 antagonizes canonical Wnt signaling by binding to LRP5/6, preventing its interaction with the Wnt-Frizzled complex,
our data suggest that NELL-1 stimulates canonical Wnt by extracellular mechanisms. The small molecule XAV939, which blocks Wnt signaling by intracellular mechanisms, also abrogated the canonical Wnt response to NELL-1, further verifying the function of NELL-1 in this pathway. Our ongoing study of the mechanisms of NELL-1 activation of Wnt signaling, via integrin-β1 or other cell surface receptors, will greatly improve our mechanistic understanding of NELL-1 functions.
Cellular Effects of NELL-1 and BMP2 in Femoral Segmental Defect Healing
Controlling the proper differentiation of local progenitor cells in the defect space is a highly regulated process crucial for normal bone development, maintenance, and healing after injury.
Bone morphogenetic protein-2 and transforming growth factor-beta2 interact to modulate human bone marrow stromal cell proliferation and differentiation.
or chemotactically recruiting mesenchymal progenitors from the bone marrow or neighboring compartments such as the periosteum and the surrounding muscle and soft tissues.
These mechanisms all increase the number of cells at the defect site and may contribute to the reactive tissue zone induced by clinically relevant, high-dose BMP2
(Figure 1). Indeed, we found increased proliferation and decreased apoptosis on BMP2 treatment (Supplemental Figure S3), correlating with the increased cellularity induced by BMP2 (Figure 3). Another interesting aspect is the precise cellular constituent that was responsive to NELL-1 and BMP2 in our model. A femoral bone defect environment will expose multiple, distinct cell types to exogenous BMP2 and NELL-1 protein, including BMSCs, endosteal/periosteal progenitor cells, and cortical osteoblasts. Prior studies from our research group have confirmed that multiple cell types are NELL-1 responsive. For example, NELL-1 induction of osteogenesis is best studied in BMSCs
Although complex, Understanding the cell-specific responses to NELL-1 and BMP2 treatment may allow for future refinements in protein-based methods of tissue engineering.
Here, NELL-1 alone, delivered from a synthetic PLGA carrier, resulted in limited osteogenesis at the defect margins (Supplemental Figure S1), a location adjacent to the periosteum and bone marrow, which are sources of BMPs and BMSCs.
In contrast, we have shown that NELL-1 treatment alone can induce complete defect healing using a demineralized bone matrix carrier, which contains residual BMPs.
Based on these observations, we believe that NELL-1 is not directly chemotactic, but instead promotes a more directed lineage specification of BMP2-induced or recruited progenitors toward osteogenesis, while at the same time inhibiting adipogenic lineage commitment. Indeed, we observed reduced cellularity (Supplemental Figure S3) and adipogenesis (Figures 2 and 3) with NELL-1+BMP2 cotreatment compared with BMP2 treatment alone. Just as BMPs have differing effects depending on cell subpopulation,
an important future direction will be to identify the precise cell populations targeted by NELL-1 in vivo to further improve its osteoinductive potential.
McKay B: Science-based assessment: accelerating product development of combination medical devices. Presented at the 7th National Materials and Manufacturing Board Roundtable on Biomedical Engineering Materials and Applications. 2003 February 11, Washington, DC
low BMP2 doses (<150 μg/mL) induce osteogenesis and bone healing in rat FSDs but do not elicit adipogenic effects. We did find that treatment groups receiving lesser doses of BMP2 supplemented with NELL-1 achieved radiographic scores greater than those from groups receiving BMP2 alone (data not shown). Because NELL-1 can improve bone formation even if lesser BMP2 doses are used, an interesting future direction would be to test whether the combination of NELL-1 with BMP2 can reduce the currently required clinical dose of BMP2, to potentially reduce the adverse effects of high-dose BMP2.
Because NELL-1 alone significantly inhibits PPARγ expression (Figure 4), it may also have an inherent suppressive effect on adipogenesis independent of BMP2-induced adipogenesis.
Because canonical Wnt inhibitors did not completely eliminate the antiadipogenic effect of NELL-1 on BMP2-induced adipogenesis, we hypothesize that other pathways, such as Hedgehog signaling, may be involved in adipogenic regulation.
The ability of NELL-1 to activate Wnt signaling suggests potential utility in conditions such as osteoporosis, in which the balance between osteogenesis versus adipogenesis and the balance between bone deposition versus resorption are perturbed to favor bone loss.
In fact, in recognition of the importance of Wnt signaling in bone disease in humans, antibodies against two endogenous Wnt pathway inhibitors, sclerostin and DKK-1, are currently in Phase 2 clinical trials in osteoporosis.
Thus, NELL-1 stimulation of Wnt signaling may not only repress PPARγ to increase osteoblastogenesis but also reduce osteoclastogenesis and associated bone loss.
and present studies demonstrate a strong mechanistic rationale for combining NELL-1 with BMP2 to significantly improve the safety and efficacy of the currently clinically available bone-regeneration capabilities. The combination treatment of NELL-1 with BMP2 may be particularly valuable in clinical scenarios in which bone regeneration is impaired, such as in patients undergoing corticosteroid treatment or having osteoporosis. In addition, the novel ability of NELL-1 to stimulate Wnt signaling and to repress adipogenesis may highlight new treatment approaches for osteoporotic bone loss that aim to both increase osteoblastogenesis and decrease osteoclastogenesis.
Acknowledgments
We thank the Translational Pathology Core Laboratory and the Division of Surgical Pathology (UCLA Department of Pathology and Laboratory Medicine) for technical assistance with histological examination and Statistical Consulting Services (UCLA Academic Technology Services).
J.S., X.Z., S.P., K.T., and C.S. designed the study; J.S., R.K.S., X.Z., S.P., and J.N.Z. performed experiments; J.S., R.K.S., X.Z., J.N.Z., K.K., and M.L. collected data; J.S., A.W.J., K.K., A.N., and K.S.L. analyzed data; J.S., R.K.S., X.Z., A.W.J., S.T., K.T., and C.S. interpreted data; J.S. and R.K.S. wrote the manuscript; and J.S., R.K.S., X.Z., J.N.Z., A.W.J., K.S.L., and S.T. revised the manuscript. K.T. and C.S. take responsibility for the integrity of the data analysis.
Supplemental Data
Supplemental Figure S1A and B: Hematoxylin and eosin (H&E) (A) and trichrome (B) staining of femoral segmental defect treated with 600 μg/mL NEL-like molecule-1 (NELL-1) at 12 weeks after surgery, demonstrating limited osteogenesis at the distal cut edge of the defect. The boxed area indicates the region magnified in B. C: Two-dimensional (2D) radiography, sagittal section, axial section, and three-dimensional (3D) reconstructed microcomputer tomography (microCT) images. The boxed area indicates the region of interest selected for microCT reconstruction. Scale bars: 4 mm (A); 1 mm (B); and 5 mm (C).
Supplemental Figure S2A:In vitro analysis of NEL-like molecule-1 (NELL-1) and/or bone morphogenetic protein 2 (BMP2) effects on adipogenesis in rat bone marrow stromal cells treated with phosphate-buffered saline, 800 ng/mL NELL-1, and/or 300 ng/mL BMP2 under adipogenic differentiation conditions. Peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer-binding protein α (C/EBPα) mRNA levels were determined on day 3 by real-time PCR as shown in the graphs, and PPARγ protein was detected by Western blot analysis. B: Regulation of NELL-1 and BMP2 on Smad phosphorylation. M2-10B4 cells were treated with NELL-1 and/or BMP2 after serum starvation in RPMI 1640 + 1% fetal bovine serum overnight. The levels of phosphorylated Smad1/5/8 (p-Smad) and total Smad1/5/8 (Smad) were analyzed by Western blot analysis. ∗∗P < 0.01 versus control group; ††P < 0.01 versus same dose of BMP2. n = 3 (A and B). Min, minute; Mins, minutes.
Supplemental Figure S3A: Staining of the cell-division marker proliferating-cell nuclear antigen (PCNA) within the defect site. Increased proliferation in the bone morphogenetic protein 2 (BMP2)-only group, consistent with increased cellularity and inflammation, is observed. NEL-like molecule-1 (NELL-1) + BMP2 co-treatment resolves the proliferation response induced by BMP2. B: Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining of apoptotic cells within the defect site. BMP2 treatment alone reduces apoptosis in the defect space relative to controls, whereas NELL-1+BMP2 co-treatment samples exhibit apoptosis similar to that in controls. C: Quantification of PCNA staining in A. D: Quantification of TUNEL staining in B. ∗P < 0.05, ∗∗P < 0.01 versus control group; ††P < 0.01 versus same dose of BMP2. n = 3 (C and D). Scale bars, 0.2 mm (A and B).
Siu RK, Zhang X, Ko T, Wu BM, Ting K, Culiat CT, Soo C: Nell-1 deficient mice exhibit abnormal structure in spinal and long bones. Presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research. 2009 September 11-14, Denver, CO
Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression.
Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways.
Bone morphogenetic protein-2 and transforming growth factor-beta2 interact to modulate human bone marrow stromal cell proliferation and differentiation.
McKay B: Science-based assessment: accelerating product development of combination medical devices. Presented at the 7th National Materials and Manufacturing Board Roundtable on Biomedical Engineering Materials and Applications. 2003 February 11, Washington, DC
Supported by the California Institute for Regenerative Medicine Early Translational II Research Award TR2-01821 (C.S.); NIH/NIDCR grants R21 DE0177711 (C.S.), RO1 DE01607 (K.T.), and RO1 AR061399-01A1 (C.S.); University of California Discovery grant 07-10677 (C.S.); Eli & Edythe Broad Center of Regenerative Medicine; and a Stem Cell Research at UCLA Innovation Award. R.K.S. and A.W.J. were supported by T32 training fellowship 5T32DE007296-14. J.N.Z. was supported by CIRM training fellowship TG2-01169.
Disclosures: K.T. and C.S. are inventors of NELL-1–related patents and are founders of Bone Biologics Inc., which sublicenses NELL-1 patents from the UC Regents.
00594-5&id=gr1.jpg){kind=link}
00594-5&id=gr2.jpg){kind=link}
00594-5&id=gr3.jpg){kind=link}
00594-5&id=gr4.jpg){kind=link}
00594-5&id=gr5.jpg){kind=link}
00594-5&id=gr6.jpg){kind=link}
00594-5&id=figs1.jpg){kind=link}
00594-5&id=figs2.jpg){kind=link}
00594-5&id=figs3.jpg){kind=link}